Celltrion, Inc.
068270 · Korea Exchange (KRX) — KOSPI · Healthcare — Biotechnology (Biosimilars)
About the company
Celltrion is South Korea's leading biotechnology company and a global pioneer in biosimilar drug development and manufacturing, producing biosimilars of infliximab (Remsima), trastuzumab (Herzuma), rituximab (Truxima), and other biologics. The company merged with Celltrion Healthcare in 2023 to create a fully integrated biopharmaceutical company spanning discovery to commercialization. Celltrion's biosimilar portfolio is marketed in over 100 countries.
| Exchange | Korea Exchange (KRX) — KOSPI |
| Ticker | 068270 |
| Sector | Healthcare — Biotechnology (Biosimilars) |
| Indicative market cap USD | $25.00B |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
On its home market (Korea Exchange (KRX) — KOSPI), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange — official exchange listing
Availability information only — not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in South Korea
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only — not investment advice. Verify with the exchange, the company's filings and your broker.